Evolent Health, Inc. (NYSE:EVH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Evolent Health, Inc. (NYSE:EVH) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $43.00.

Several research firms recently commented on EVH. Oppenheimer began coverage on shares of Evolent Health in a report on Friday, March 1st. They issued an “outperform” rating and a $45.00 price objective for the company. Canaccord Genuity Group decreased their target price on Evolent Health from $45.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, March 28th. Barclays began coverage on Evolent Health in a report on Wednesday, January 3rd. They set an “overweight” rating and a $39.00 price objective for the company. JMP Securities lifted their target price on shares of Evolent Health from $37.00 to $38.00 and gave the company a “market outperform” rating in a research report on Friday, February 23rd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Evolent Health from $53.00 to $52.00 and set an “overweight” rating on the stock in a report on Friday, March 15th.

Evolent Health Trading Down 0.4 %

NYSE:EVH opened at $29.51 on Friday. The firm has a 50-day moving average price of $31.97 and a two-hundred day moving average price of $30.18. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.01. Evolent Health has a 52 week low of $23.33 and a 52 week high of $36.70. The firm has a market cap of $3.41 billion, a price-to-earnings ratio of -23.24 and a beta of 1.53.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, February 22nd. The technology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.13. Evolent Health had a negative net margin of 5.76% and a positive return on equity of 6.60%. The company had revenue of $556.06 million during the quarter, compared to analyst estimates of $541.87 million. On average, equities analysts expect that Evolent Health will post 0.87 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Evolent Health

Several institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its position in Evolent Health by 16.6% during the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after buying an additional 350 shares during the period. First Republic Investment Management Inc. boosted its position in Evolent Health by 1.6% during the 1st quarter. First Republic Investment Management Inc. now owns 22,005 shares of the technology company’s stock valued at $711,000 after buying an additional 355 shares during the period. Legal & General Group Plc boosted its position in Evolent Health by 0.3% during the 4th quarter. Legal & General Group Plc now owns 112,250 shares of the technology company’s stock valued at $3,708,000 after buying an additional 390 shares during the period. SeaCrest Wealth Management LLC boosted its position in Evolent Health by 4.4% during the 4th quarter. SeaCrest Wealth Management LLC now owns 9,500 shares of the technology company’s stock valued at $267,000 after buying an additional 400 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in Evolent Health by 1.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 33,256 shares of the technology company’s stock valued at $934,000 after buying an additional 402 shares during the period.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.